(51) International Patent Classification:
    C12P 21/08 (2006.01)   A61K 39/395 (2006.01)
    C07K 16/00 (2006.01)
(21) International Application Number:
    PCT/US2006/005676
(22) International Filing Date:
    15 February 2006 (15.02.2006)
(25) Filing Language:
    English
(26) Publication Language:
    English
(30) Priority Data:
    60/653,587   15 February 2005 (15.02.2005)   US
    60/702,063   22 July 2005 (22.07.2005)   US
(71) Applicant (for all designated States except US):
    DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Box 90083878, Durham, North Carolina (US).
(72) Inventors:
    TEDDER, Thomas, F. [US/US]; 3000 Wilde Meadow Drive, Durham, North Carolina 27705 (US).
    HAMAGUCHI, Yasuhito [JP/JP]; Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641 (JP).
    GRON, Hanne [DK/US]; 5 Winthrop Court, Durham, North Carolina 27707 (US).

Title: ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY

Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD 19 antigen and that preferably mediate human ADC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD 19 antibodies.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC: C12P 21/08 (2006.01); C07K 16/00 (2006.01); A61K 39/395 (2006.01)

USPC: 530/387.3, 388.1.1, 388.73, 388.8, 391.7, 424/133.1, 141.1, 155.1, 181.1, 183.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S.: 550/387.3, 388.1, 388.73, 388.8, 391.7, 424/133.1, 141.1, 155.1, 181.1, 183.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 6,306,393 B1 (GOLDENBERG) 23 October 2001 (23.10.2001), see entire document,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>especially columns 2, 5-7, 10-17.</td>
<td>1-22, 25-38, 40-51,</td>
</tr>
<tr>
<td>Y</td>
<td>US 5,530,101 A (QUEEN et al.) 25 June 1996 (25.06.1996), see entire document.</td>
<td>54-63</td>
</tr>
</tbody>
</table>

□ Further documents are listed in the continuation of Box C. □ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referred to in an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

"U" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"W" document member of the same patent family

Date of the actual completion of the international search 22 August 2006 (22.08.2006)

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Form PCT/ISA/210 (second sheet) (April 2005)

International application No.
PCT/US06/05876
Continuation of B. FIELDS SEARCHED Item 3:
WEST, Medline, embase, scisearch, lifesci, biotechno, biotechabs, biosis, dissabs
Search terms: CD19 antibody, humanized, chimeric, isotype, CD20, CD22, inventor search